Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr 10;25(1):238.
doi: 10.1186/s12876-025-03833-y.

Metabolic score for visceral fat is correlated with all-cause and cardiovascular mortality among individuals with non-alcoholic fatty liver disease

Chunming Xie #  1 , Xianpei Chen #  2 , Jiakun Zhang  1 , Xueqing Jiang  2 , Jing Xu  3 , Hao Lin  4
Affiliations

Metabolic score for visceral fat is correlated with all-cause and cardiovascular mortality among individuals with non-alcoholic fatty liver disease

Chunming Xie et al. BMC Gastroenterol. .

Abstract

Background: Metabolic score for visceral fat (METS-VF) as an effective marker of visceral obesity has been correlated with non-alcoholic fatty liver disease (NAFLD). This study aims to explore the correlation between METS-VF and both all-cause mortality and cardiovascular disease (CVD)-related mortality among individuals with NAFLD.

Methods: A cohort of 6,759 subjects diagnosed with NAFLD was selected from the NHANES during the period from 1999 to 2018. Within this cohort, the prognostic utility of METS-VF for predicting CVD-related and all-cause mortality was assessed.

Results: There was a total of 1254 all-cause deaths (18.6%) and 418 CVD-related deaths (6.2%) at a median follow-up for 9.3 years. Multivariate Cox regression analysis and restricted cubic splines analysis indicated that METS-VF can exhibit a positive non-linearly correlation with CVD mortality (HR: 4.15, 95% CI: 2.31-7.44, p < 0.001) and all-cause mortality (HR: 5.27, 95% CI: 3.75-7.42, p < 0.001), with an identified inflection point at 7.436. Subgroup analyses further revealed a stronger correlation between METS-VF and all-cause mortality among subjects without diabetes. Furthermore, the areas under the curve (AUC) for 1-, 3-, 5-, and 10-year survival rates were 0.756, 0.740, 0.747 and 0.746 for all-cause mortality, and 0.774, 0.751, 0.746 and 0.758 for CVD mortality, respectively, which performs better than the other obesity and IR related index.

Conclusion: Elevated METS-VF independently contributes to an increased risk of both all-cause and CVD mortality in individuals with NAFLD.

Clinical trial number: Not applicable.

Keywords: Insulin resistance; METS-VF; NAFLD; Obesity; Visceral obesity.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: The National Center for Health Statistics Ethics Review Board has approved the implementation of NHANES, and every participant signed informed consent. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Flowchart of the sample selection from the 1999–2018 NHANES
Fig. 2
Fig. 2
Kaplan–Meier curves depicting survival rate and the number (%) of a NAFLD population stratified by METS-VF groups. A. All-cause mortality. B. CVD mortality
Fig. 3
Fig. 3
Dose-response curve of METS-VF and all-cause mortality (A) and CVD mortality (B) using restricted cubic splines
Fig. 4
Fig. 4
Exploratory stratified analysis of the associations between METS-VF and All-cause(A) or CVD mortality(B)
Fig. 5
Fig. 5
Time-dependent ROC curves and time-dependent AUC values of the METS-VF for predicting all-cause mortality (A, B) and CVD mortality (C, D)
See this image and copyright information in PMC

References

    1. Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, George J, Bugianesi E. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15(1):11–20. - PubMed
    1. Lee CM, Yoon EL, Kim M, Kang BK, Cho S, Nah EH, Jun DW. Prevalence, distribution, and hepatic fibrosis burden of the different subtypes of steatotic liver disease in primary care settings. Hepatology. 2024;79(6):1393–400. - PubMed
    1. Paik JM, Henry L, Younossi Y, Ong J, Alqahtani S, Younossi ZM. The burden of nonalcoholic fatty liver disease (NAFLD) is rapidly growing in every region of the world from 1990 to 2019. Hepatol Commun 2023, 7(10). - PMC - PubMed
    1. Hartmann P, Zhang X, Loomba R, Schnabl B. Global and National prevalence of nonalcoholic fatty liver disease in adolescents: an analysis of the global burden of disease study 2019. Hepatology. 2023;78(4):1168–81. - PMC - PubMed
    1. Lee ECZ, Anand VV, Razavi AC, Alebna PL, Muthiah MD, Siddiqui MS, Chew NWS, Mehta A. The global epidemic of metabolic fatty liver disease. Curr Cardiol Rep. 2024;26(4):199–210. - PubMed

LinkOut - more resources